Loading...
Loading...
Puma Biotechnology, Inc.
PBYI, a development stage biopharmaceutical
company, announced the closing of the underwritten public offering of
8,625,000 shares of its common stock at a price to the public of $16.00 per
share. The shares of common stock issued in the offering included 1,125,000
shares of common stock issued upon the exercise in full by the underwriters of
their option to purchase additional shares. The net proceeds from the offering
were approximately $129.1 million, after deducting the underwriting discount
and estimated offering expenses payable by the Company.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in